ReviewThrombosis journal2025
Abnormalities of hemostasis in sickle cell patients and predisposition to thrombotic risk: a systematic review and meta-analysis.
Review in Thrombosis journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Oxidative Stress, Antioxidant Capacity, Dyslipidemia and Cardiovascular Risk in Sickle Cell Disease: A Systematic Review and Meta-Analysis.TheScientificWorldJournal · 2026Pooled it
- Hepatic Enzyme Abnormalities and Their Association With Hematological Parameters in Sickle Cell Disease: A Case-Control Study in Cameroon.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSickle cell disease is a hemoglobinopathy characterized by alterations in the components of hemostasis. Despite efforts and individual and multiple studies carried out to understand the pathophysiology of the disease, particularly regarding abnormalities of hemostasis and coagulation, questions remain. This meta-analysis aimed to evaluate the studies linking inflammatory, coagulation, and fibrinolysis abnormalities in sickle cell patients, putting them in an intrinsic state of hypercoagulability and predisposing them to thrombotic risk.
methodsThe systematic review of databases and search engines was conducted over 24 years (2000-2024) and worldwide according to the reporting guidelines of PRISMA and the Cochrane Handbook. The research articles listed were searched in the PubMed and Web of Science databases. Only case-control articles were retained. Data were extracted from the articles and analyzed using the statistical software R version 4.3.2. The standardized mean difference (SMD) was used to assess the extent of the disease on the different parameters studied. Heterogeneity across individual studies was assessed using Higgins's inconsistency Q statistics and reported as I
results303 studies were initially identified; after the elimination of duplicates and of works not meeting the objective of the study, 17 studies were finally included for meta-analyses. The standardized mean difference (SMD) using the common effect model is 0.79 [0.58, 1.00] for prothrombin time for 5 studies analyzed (p < 0.01), 0.26 [0.06, 0.46] for fibrinogen for 6 studies analyzed (p < 0.01), and 0.87 [0.62, 1.11] for D-dimer for 6 studies analyzed (p < 0.01); thus reflecting the strong influence of sickle cell disease on the production of Prothrombin, fibrinogen and D-dimer when compared to normal controls. For protein C, the SMD with the common effect model is -1.32 [-1.54, -1.09] for 5 studies analyzed (p < 0.01), and for protein S, it is -1.45 [-1.69, -1.22] for 5 studies analyzed (p < 0.01); thus reflecting a significant negative influence of sickle cell disease on protein C and protein S production when compared to normal controls. Finally, the SMD for antithrombin using the common effect model is 0.66 [0.35, 0.98] for 5 studies analyzed (p < 0.01), thus reflecting the strong influence of sickle cell disease on the production of antithrombin when compared to normal controls.
conclusionAnalyses performed from these studies reported a large influence of sickle cell disease on the inflammatory, coagulation, fibrinolysis, and natural anticoagulant system when compared to normal controls, assessed by a SMD that ranged from moderate to large. These results provide more information on research related to coagulation abnormalities in sickle cell disease and will help improve patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.